

The Biochemistry Behind Cognitive Decline: Biomarkers of Alzheimer's Disease

O.Grari^{1,2}, D.Elmoujtahide^{1,2}, E.Sebbar^{1,2}, M.Choukri^{1,2}

1: Faculty of Medicine and Pharmacy, Mohammed I University, Oujda, Morocco

2: Department of Biochemistry, Mohammed VI University Hospital, Oujda, Morocco

Article Info

Author of correspondence:

Dr. Oussama Grari

Medical Resident in laboratory medicine;

E-mail: oussama.grari@ump.ac.ma;

Address:

Central Laboratory, Mohammed VI University Hospital of
Oujda, Thami Jilali Avenue 60050, Oujda, Morocco

Keywords

Alzheimer's disease, Biomarkers, Cerebrospinal fluid,
Amyloid β peptide, Tau protein, Neurofibrillary tangles

Abstract

Alzheimer's disease (AD) is the most prevalent type of dementia. Pathologically, the disease is marked by neurofibrillary tangles (NFT), which are aberrant accumulations of the tau protein that develop inside neurons, and extracellular plaque deposits of the amyloid β peptide (A β). These pathological lesions are present in the brain before the beginning of clinical manifestations. However, despite advancements in the comprehension of AD pathophysiology, timely and accurate clinical diagnosis remains challenging. Therefore, developing biomarkers capable of detecting AD during the preclinical phase holds enormous promise for precise diagnosis since detecting the disease early is crucial because it enables interventions when treatments may be more effective. This article intends to provide a comprehensive review of AD biomarkers, discussing their significance, classification, and recent developments in the field.

Abbreviations:

NFT: neurofibrillary tangles, APP: amyloid precursor protein, PSEN1: presenilin1, PSEN2: presenilin2, SPECT: single photon emission computed tomography, CT: computed tomography, FDG-PET: 18F-fluorodeoxyglucose-positron emission tomography, MRI: magnetic resonance imaging, CSF: cerebrospinal fluid, BBAD: blood biomarkers in AD

Introduction:

Alzheimer's disease (AD) was discovered more than a century ago. It is the most common neurodegenerative disorder in older adults, which results in loss of memory, language, visuospatial abilities, and other mental functions (1). Worldwide, the case rate of AD doubles every five years after age 65. In addition, it is expected that there will be 115 million cases by 2050 (2). People suffering from the disease's latter stages are bedridden and need care 24 hours daily. AD is eventually fatal. According to researchers, early AD diagnosis will be crucial to halting, slowing, or delaying the illness. Therefore, much attention is being put on understanding AD's pathophysiology and establishing early diagnosis and efficient intervention due to the disease's severe economic and societal costs.

Pathophysiologically, AD is characterized by extracellular deposits of the protein beta-amyloid (also known as beta-amyloid plaques) and the buildup of a particular type of protein tau (also known as tau tangles) inside neurons. These changes lead to the destruction of neurons that cause memory loss and other symptoms of AD (3). Physicians typically rely on clinical symptoms for diagnosing AD. However, neuronal loss and neuropathologic lesions are already evident in many brain regions when AD is clinically diagnosed (3). A key objective of biomedical research is identifying preclinical markers of AD (i.e., biomarkers) that permit early diagnosis and intervention. These biomarkers enable clinicians to recognize individuals at risk before observable cognitive decline, thereby allowing for potentially more effective early interventions to preserve cognitive function. This article aims to provide a concise and current overview of AD biomarkers, focusing on their importance in early detection, diagnosis, and treatment monitoring and

discussing the challenges associated with their application.

Understanding AD:

Risk factors:

AD, a complex neurodegenerative condition, has been related to a number of risk factors. While age remains the most critical risk factor, research has shown many other characteristics contributing to an individual's susceptibility to the disease. The major other unmodifiable risk factor is genetic, with one APOE $\epsilon 4$ allele raising the risk of developing AD threefold, and two APOE $\epsilon 4$ alleles increasing the risk up to twelvefold. Modifiable risk factors for AD include hypertension, diabetes, hypercholesterolemia, smoking, alcohol consumption, obesity, and diet. On the other hand, physical activity, education, entertainment, and social interaction have all been proven protective factors (4). Table 1 summarizes some of the major risk factors for AD.

Table 1: AD risk factors

Risk factor	Description
Age	The main risk factor for AD is advancing age, with 10–30% prevalence in the population older than 65, with an incidence at least doubling every ten years after age 60 (5).
Sex	Women are more likely to develop AD.
Genetics	<ul style="list-style-type: none"> - Family history of AD - The existence of the APOE $\epsilon 4$ allele - Trisomy 21 and family history are risk factors for early-onset dementia.
Lifestyle Factors	Cardiovascular health, which involves hypertension and elevated cholesterol, smoking, obesity, diabetes, dietary habits, physical inactivity, and lack of intellectual and social activity (6).
Environmental Factors	Exposure to toxins or certain chemicals and traumatic brain injuries.
Mental Health	Conditions like depression and chronic stress increase the risk of AD.
Sleep Disorders	Sleep disturbances may contribute to cognitive decline.

Abbreviations: AD: Alzheimer's disease; APOE $\epsilon 4$: apolipoprotein E- $\epsilon 4$;

Pathophysiology:

AD is marked by brain shrinkage and abnormal deposits called plaques and neurofibrillary tangles (NFT). Plaques are microscopic lesions characterized by a spherical shape, consisting of an extracellular core composed of amyloid beta (A β) peptide. At the same time, NFT are intracytoplasmic structures and consist of twisted coupled spiral fibrillary proteins known as tau, found within neurons. The amyloid precursor protein (APP) is a membrane protein that is found mostly in synapses. In standard non-amyloidogenic processing, APP undergoes cleavage by α -secretase, followed by γ -secretase. Subsequently, the resulting fragments are processed and removed correctly. In individuals diagnosed with AD, the amyloidogenic processing pathway involves the sequential action of β -secretase and γ -secretase on APP, resulting in the generation of amyloid- β (A β) fragments, with a specific emphasis on A β 1-42. Extracellular plaques arise as a result of the increased accumulation in conjunction with reduced clearance processes. A β deposits form around meningeal and cerebral blood vessels, as well as gray matter. Tau is a protein that stabilizes the microtubule in neuronal axons in a healthy state. Due to the extracellular A β aggregation in AD, tau is hyperphosphorylated, which leads to tau aggregates and polymerization into fibrillar structures that destabilize microtubules and produce NFT, which are found within both glial and neuronal cell types in the affected cortical and subcortical brain regions. The presence of these pathogenic proteins and free radicals leads to the activation of microglia, neuroinflammation, damage to mitochondria, oxidative stress, deficits in neurotransmitters (specifically acetylcholine), malfunction in synaptic activity, and finally, the loss of synapses and neurons, which leads to memory loss and cognitive deterioration(5–8).

Challenges in Clinical Diagnosis:

While our understanding of AD biology has evolved significantly, diagnosing the disease remains challenging. The medical diagnosis of AD relies on conducting neuropsychological assessments, which typically involve evaluating memory loss and cognitive decline and carefully excluding other dementias commonly occurring with advancing age, among them cerebrovascular disease, dementia with Lewy bodies, cerebral tumor, normal pressure hydrocephalus, frontotemporal lobar degeneration, or depression (9,10). The clinical identification of AD exhibits limited reliability, particularly in the initial phases of the disease. Based on autopsy validation, the clinical diagnosis of AD compared to non-AD conditions demonstrates an overall accuracy rate of 78% (11). Misdiagnosis of AD is especially common in its initial phases when signs are subtle or mild, and in primary care, in which over half of patients having cognitive impairment are not detected or appropriately diagnosed (12). This misinterpretation leads to inadequate care and treatment, retarded or erroneous interventions, and incorrect data regarding

condition and outcome (13). Neuropathological alterations occur years before clinical manifestations of AD. Pathological NFT composed of phosphorylated tau protein accumulate in brain cells during the presymptomatic stages of AD. In addition, distinct isoforms of amyloid- β (A β) peptide deposits accumulate in the extracellular space. These proteins are secreted into the CSF, where they are detectable (14). Efforts have been undertaken in recent years to develop reliable biomarkers and sophisticated imaging techniques to aid in early and accurate AD diagnosis, thereby addressing a significant need in clinical practice.

AD biomarkers:

Biomarkers: Definition and Types:

A biomarker is a measurable characteristic that signals healthy physiological functions, pathologic biological events or biological reactions to an exposure or intervention, which include therapeutic responses. Biomarkers can consist of molecular, histologic, radiographic, or physiological traits. Biomarkers fall into the following categories: susceptibility/risk, diagnostic, monitoring, prognostic, and predictive biomarkers (15). The perfect AD biomarker should meet several requirements, including 1) being able to identify AD with high specificity and sensitivity; 2) the aptitude to recognize the earliest stages and monitor the evolution of AD; 3) usefulness for assessing medical effectiveness; and 4) the need for specimens which could be collected quickly, numerous times, in a noninvasive manner, and affordably (16). Biomarkers for AD include genetic markers (17), neuroimaging markers such as PET scans and MRI (18), and biochemical markers such as amyloid beta and tau proteins (19).

Genetic Biomarkers:

The genes A β PP, PSEN1, and PSEN2 have been significantly associated with the development of early-onset AD, which often manifests before age 65 and is exceptional (5% of AD cases). On the other hand, late-onset AD (the most prevalent form) has primarily been linked to the apolipoprotein E- ϵ 4 (APOE ϵ 4) gene, which is suggested to elevate AD risk essentially by modulating A β accumulation (20,21). Genetic AD biomarkers (mutations in A β PP, PSEN1, and PSEN2) are just helpful in detecting familial AD (more than 95% of AD cases are isolated and lack mutations in these three genes). On the other hand, the APOE ϵ 4 mutation is a known risk factor for late-onset AD, but it is not a reliable genetic biomarker for diagnosis. Because of lower prices and faster analysis, testing for AD-associated genes using focused sequencing methods such as Sanger or next-generation sequencing became increasingly popular compared to complete-exome sequencing over time. Nevertheless, genetic testing for AD is not usually recommended. It is sometimes used in families with rare early-onset forms of AD (6).

Neuroimaging-based Biomarkers in AD:

Human in vivo neuroimaging provides a deeper comprehension of the pathophysiology of AD. These examinations are essential for identifying non-AD etiologies contributing to cognitive loss (e.g., strokes or cerebral tumors) and providing diagnostic support for AD (22). MRI and CT allow visualization of gray matter, white matter, and CSF. They help characterize supportive features for diagnosing AD, especially brain atrophy. They also permit the elimination of non-AD causes of cognitive decline (22). The PET scan is another neuroimaging technique commonly used in AD research and diagnosis. It works with radiolabeled tracers specific to A β , such as Flutemetamol, Pittsburg compound B, and F-florbetapir (23,24). Other Functional neuroimaging techniques for identifying dysfunctional brain regions include functional MRI (fMRI), which examines blood flow in the brain, and SPECT, which investigates brain perfusion as a measure of brain metabolism. Despite their contributions to our comprehension of AD, these neuroimaging techniques have limitations that must be considered—specifically, the requirement for costly equipment and specialized training.

CSF Biomarkers in AD:

Because the brain's extracellular space is in intimate contact with the CSF, modifications in the physiology of nervous system may be detected in the CSF. The two most well-known neuropathologic signs of AD are A β deposits and tau protein NFT. CSF biomarkers that have been established reflect the pathophysiology of these two features. When comparing AD patients to normal controls, A β 1-42 concentrations in CSF are lower, although total tau (T-tau) and phosphorylated tau (P-tau) concentrations are higher. This decline in A β 1-42 in the CSF of Alzheimer's patients occurs because A β accumulates into plaques, trapping the peptide in cerebral tissue, resulting in a decreased capacity for A β to diffuse into the CSF (25). Tau found in CSF may be associated with the passive discharge of intracellular content from dead cells. Still, multiple studies show that tau secretion also involves active cellular processes (26). In contrast to A β , NFT appear later in the progression of AD (27). Moreover, high CSF tau has been linked with rapid transformation from mild cognitive impairment to AD, tissue injury, and the likelihood of poor clinical outcome (28–30). T-tau is not specific to AD but indicates brain degeneration or injury. It is elevated in the brains of various neurodegenerative disease patients (25). On the contrary, increased P-tau, which denotes hyperphosphorylated tau protein, is associated with NFT formation in the brain (31,32). A β 1-42 and tau Protein can be measured using immunological techniques such as ELISA and electrochemiluminescence and non-immunological techniques such as mass spectrometry (MS). Multiple studies supported by evidence have shown that using the CSF A β 1-42/1-40 ratio is more effective than the total amount of CSF A β 1-42. This approach enhances the accuracy of diagnoses. Similarly, in terms

of PET scan consistency, using CSF P-tau/A β 1-42 or T-tau/A β 1-42 ratios is more reliable compared to relying exclusively on T-tau or P-tau, respectively, or A β 1-42 alone (33,34). However, the significant inter-laboratory variability in analyte concentrations can restrict the usefulness of CSF biomarker assays. Therefore, it is necessary to enhance assay development quality control specifications to assure minimal total calibration variation and strict variability limits between lots(19). For this reason, The Alzheimer's Association Quality Control program for CSF biomarkers, which includes 84 laboratories worldwide, and the Working Group for CSF proteins of the International Federation of Clinical Chemistry (IFCC) have initiated work to create uniform procedures and unify levels between assay techniques to tackle these problems and adjust results over laboratories (24). According to a recent meta-analysis (35), clinicians can use CSF biomarkers as a valuable supplementary diagnostic test when evaluating patients with cognitive disorders. Specifically, CSF biomarkers enhanced physicians' assurance of diagnosing AD and impacted patient management. It is advisable to include CSF AD biomarkers as a standard practice in assessing patients with mild cognitive impairment and dementia. They are suggested for accurate and timely diagnosis, differential diagnosis, and predicting the probability and progression of neurological deterioration (36). The kits and methods that are often used for measuring CSF Biomarkers of AD are included in Table 2.

Blood biomarkers in AD (BBAD):

Given the invasiveness and cost of CSF and neuroimaging biomarkers of AD, there is a pressing need to explore and develop reliable BBAD. Despite the common perception that AD is a brain disease, it has been shown that AD is a systemic condition which manifests in peripheral tissues beyond the central nervous system (CNS) throughout the earlier stages of the disease. Furthermore, biomolecules are continuously exchanged between the circulation and CSF (37). The latest innovations in BBAD for identification, prognosis, and monitoring therapy include plasma A β 1-42/1-40 ratio, P-tau levels, serum neurofilament light chain, and glial fibrillary acidic protein (38). However, several difficulties must be addressed before BBAD may be considered a routine component of clinical therapy. Interference of circulating blood proteins and the reduction in the concentration of proteins and other analytes as they travel from the brain tissue to the CSF and into the circulation pose a significant quantitative identification challenge (39). Moreover, there are few available prospective studies in which plasma samples were collected continuously over an extended period, and clinical efficacy was calculated from a predetermined cut point. Before adopting a specific BBAD or any combination of BBAD in clinical practice, it is recommended that such data be gathered through clinical studies (38). The kits and methods that are often used for measuring BBAD are included in Table 3.

Table 2: Kits and methods that are often used for measuring CSF

Fluid	Biomarker	Commerical kits	Technique	Label	
				USA	EU
CSF	A β 42	INNOTEST, Fujirebio	ELISA	RUO	CE Marked
		Lumipulse, Fujirebio	CLEIA	RUO	CE Marked
		Elecsys, Roche Diagnostics	ECLIA	BDD	CE Marked
		Euroimmun, PerkinElmer	ELISA	N/A	CE Marked
		TECAN, Ibl-international	ELISA	RUO	CE Marked
		ADMark, Athena Diagnostics	ELISA	LDT	N/A
	A β 42/A β 40 ratio	Lumipulse, Fujirebio	CLEIA	FDA approved	CE Marked
		Euroimmun, PerkinElmer	ELISA	N/A	CE Marked
		TECAN, Ibl-international	ELISA	RUO	CE Marked
		ABtest-IA, Araclon Biotech	ELISA	RUO	CE Marked
	P-tau-181	INNOTEST, Fujirebio	ELISA	RUO	CE Marked
		Lumipulse, Fujirebio	CLEIA	RUO	CE Marked
		Elecsys, Roche Diagnostics	ECLIA	BDD	CE Marked
		Euroimmun, PerkinElmer	ELISA	N/A	CE Marked
		TECAN, Ibl-international	ELISA	N/A	CE Marked
		ADMark, Athena Diagnostics	ELISA	LDT	N/A
	T-tau	Lumipulse, Fujirebio	CLEIA	RUO	CE Marked
		Elecsys, Roche Diagnostics	ECLIA	BDD	CE Marked
		Euroimmun, PerkinElmer	ELISA	N/A	CE Marked

Table 3: Kits and methods that are often used for measuring BBAD

Fluid	Biomarker	Commerical kits	Technique	Label	
				USA	EU
Plasma	A β 42/ A β 40 ratio	HISCL β -Amyloid, Sysmex	CLEIA	N/A	CE Marked
	P-tau-181	Simoa Advantage V2Kit, Quanterix	Single molecule array (SiMoA)	BDD	N/A
	Panels: A β 42/ A β 40 ratio, APOE ϵ 4	PrecivityAD, C ₂ N Diagnostics	LC-MS/MS	BDD	CE Marked
	P-tau-181, APOE ϵ 4	Elecsys Amyloid Plasma Panel, Roche Diagnostics	Elecsys immunoassays	BDD	N/A

Abbreviations: CSF: Cerebrospinal fluid; A β 42: Amyloid β -protein 42 ; ELISA: enzyme-linked immunosorbent assay ; RUO : Research Use Only ; CE : *Conformité Européenne* ; CLEIA: Chemiluminescence enzyme immunoassay ; ECLIA: Electrochemiluminescence immunoassay ; BDD: Breakthrough Devices Program ; N/A: not available ; LDT: Laboratory Developed Test ; A β 40: Amyloid β -protein 40 ; FDA: Food and Drug Administration ; APOE ϵ 4: apolipoprotein E- ϵ 4; LC-MS/MS: Liquid chromatography–tandem mass spectrometry

Future Directions in AD Biomarkers:

Many studies are being conducted in the area of AD biomarkers; prospects include the discovery of biomarkers that can evaluate each stage of disease pathogenesis and enable a precise diagnosis of the condition in its earliest stages. In addition, recent advances in developing proteomics, metabolomics, mass spectrometry, and using exosomes and investigating microRNA profiles revealed promising prospects for blood-based biomarkers as AD screening tools (40). Blood cell-derived biomarkers are an additional area of research with promising potential. Changes in peripheral cells such as platelets, lymphocytes, and erythrocytes have been observed in AD, rendering them potential biomarkers for studying neuronal pathology (41). Blood platelets, which share biochemical properties with neurons, can be used as a basis for comprehending the pathology of AD (42). Through the blood-brain barrier, lymphocytes, essential to neuroinflammatory processes, migrate from the circulation to the Alzheimer's brain. The combination of these neuroinflammatory elements in the blood and the alterations observed in the lymphocytes of patients with AD has the potential to serve as blood cell-based biomarkers for condition (43). The presence of molecules such as β -amyloid peptide, heat shock protein 90, band three protein, and calpain 1 in erythrocytes indicates their potential as preclinical biomarkers. Furthermore, red blood cell morphology is significantly altered in AD (44). However, despite these promising features, additional research is required to explore their diagnostic potential thoroughly (41).

Conclusion:

AD is a form of dementia characterized by irreversible progression and lengthy prodromal phases. Utilizing minimally invasive diagnostic tests that assess biomarkers might present the most effective option for diagnosing AD in its early stages instead of relying only on clinical evaluations. The use of biomarkers for AD diagnosis has gained popularity over the past two decades. However, their efficiency in early AD diagnosis and routine screening is questioned due to their employment of invasive procedures, high expense, and measurement uncertainty. PET scan and CSF markers are more often utilized diagnostic biomarkers in clinical studies; however, they have practical issues (e.g., expense and access). As sensitive and novel technical approaches are developed, and research design is given more significant thought, possibilities for biomarkers for AD will be carefully assessed.

Declaration of no conflict of interest:

The researcher has no conflict of interest to declare.

References:

1. Ji W, An K, Wang C, Wang S. Bioinformatics analysis of diagnostic biomarkers for Alzheimer's disease in peripheral blood based on sex differences and support vector machine algorithm. *Hereditas*. 2022 Dec 1;159(1).
2. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo L, Blennow K, et al. Position Paper Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria [Internet]. 2014. Vol. 13. Available from: www.thelancet.com/neurology
3. Gaugler J, James B, Johnson T, Scholz K, Weuve J. 2016 Alzheimer's disease facts and figures. *Alzheimer's and Dementia*. 2016 Apr 1;12(4):459–509.
4. Serrano-Pozo A, Growdon JH. Is Alzheimer's Disease Risk Modifiable? *Journal of Alzheimer's Disease*. IOS Press; 2019. Vol. 67, p. 795–819.
5. Eratne D, Loi SM, Farrand S, Kelso W, Velakoulis D, Looi JCL. Alzheimer's disease: clinical update on epidemiology, pathophysiology and diagnosis. *Australasian Psychiatry*. 2018 Aug 1;26(4):347–57.
6. Kumar A, Sidhu J, Goyal A, Tsao JW. *Alzheimer Disease*. Treasure Island (FL): StatPearls Publishing; 2023.
7. Calsolaro V, Edison P. Neuroinflammation in Alzheimer's disease: Current evidence and future directions. *Alzheimer's and Dementia*. Elsevier Inc.; 2016. Vol. 12, p. 719–32.
8. Schraen-Maschke S, Sergeant N, Dhaenens CM, Bombois S, Deramecourt V, Caillet-Boudin ML, et al. Tau as a biomarker of neurodegenerative diseases. *Biomarkers in Medicine*. Future Medicine Ltd.; 2008. Vol. 2, p. 363–84.
9. Larson EB, Edwards JK, O'meara E, Nochlin D, Sumi SM. Neuropathologic Diagnostic Outcomes From a Cohort of Outpatients With Suspected Dementia [Internet]. *Journal of Gerontology: MEDICAL SCIENCES*. 1996. Vol. 51, Available from: <https://academic.oup.com/biomedgerontology/article/51A/6/M313/593075>
10. Cummings JL, Vinters H V., Cole GM, Khachaturian ZS. Alzheimer's disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. *Neurology*. 1998;51(1 SUPPL.).
11. Knopman DS, Dekosky ; S T, Cummings ; J L, Chui ; H, Corey-Bloom ; J, Relkin ; N, et al. Practice parameter: diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. 2001.
12. Bradford A, Kunik ME, Schulz P, Williams SP, Singh H. Missed and delayed diagnosis of dementia in primary care: Prevalence and contributing factors. *Alzheimer Disease and Associated Disorders*. 2009. Vol. 23, p. 306–14.
13. Ghosh A. Biomarkers in Neurodegenerative Diseases [Internet]. Available from: www.mdpi.com/journal/biomedicines

14. Hu X, Meier M, Pruessner J. Challenges and opportunities of diagnostic markers of Alzheimer's disease based on structural magnetic resonance imaging, *Brain and Behavior*. John Wiley and Sons Ltd; 2023, Vol. 13
15. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK326791/> Co-published by National Institutes of Health (US), Bethesda (MD)
16. Khan TK. Biomarkers in Alzheimer's disease. Academic Press; 2016.
17. Reitz C. Genetic diagnosis and prognosis of Alzheimer's disease: Challenges and opportunities. *Expert Review of Molecular Diagnostics*. Expert Reviews Ltd.; 2015. Vol. 15, p. 339–48.
18. Lorking N, Murray AD, O'Brien JT. The use of positron emission tomography/magnetic resonance imaging in dementia: A literature review. *International Journal of Geriatric Psychiatry*. John Wiley and Sons Ltd; 2021. Vol. 36, p. 1501–13.
19. Blennow K, Dubois B, Fagan AM, Lewczuk P, De Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. *Alzheimer's and Dementia*. Elsevier Inc.; 2015. Vol. 11, p. 58–69.
20. Huynh RA, Mohan C. Alzheimer's disease: Biomarkers in the genome, blood, and cerebrospinal fluid. *Frontiers in Neurology*. Frontiers Media S.A.; 2017, Vol. 8.
21. Kumar A, Janelidze S, Stomrud E, Palmqvist S, Hansson O, Mattsson-Carlsson N. β -Amyloid-Dependent and Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease. *Neurology*. 2022 Aug 2;99(5):E476–87.
22. Ferreira LK, Busatto GF. Neuroimaging in Alzheimer's disease: Current role in clinical practice and potential future applications. *Clinics*. Universidade de Sao Paulo; 2011. Vol. 66, p. 19–24.
23. Márquez F, Yassa MA. Neuroimaging Biomarkers for Alzheimer's Disease. *Molecular Neurodegeneration*. BioMed Central Ltd.; 2019, Vol. 14.
24. Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, Zetterberg H, et al. Reference measurement procedure for CSF amyloid beta (A β)_{1–42} and the CSF A β _{1–42}/A β _{1–40} ratio – a cross-validation study against amyloid PET. *J Neurochem*. 2016 Nov 1;139(4):651–8.
25. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. *Nature Reviews Neurology*. 2010. Vol. 6, p. 131–44.
26. Brunello CA, Merezhko M, Uronen RL, Huttunen HJ. Mechanisms of secretion and spreading of pathological tau protein. *Cellular and Molecular Life Sciences*. Springer; 2020. Vol. 77, p. 1721–44.
27. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kaye R, et al. Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles: Intracellular A and Synaptic Dysfunction. *Neuron*. 2003, Vol. 39. 409–421.
28. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke [Internet]. Available from: www.elsevier.com/locate/neulet
29. Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, et al. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the ApoE ϵ 4/ ϵ 4 genotype. *Dement Geriatr Cogn Disord*. 2009 Jun;27(5):458–64.
30. Zetterberg H, Albert Hietala M, Jonsson M, Andreasen N, Styrd E, Karlsson I, et al. Neurochemical Aftermath of Amateur Boxing [Internet]. Available from: <http://archneur.jamanetwork.com/>
31. de Souza LC, Chupin M, Lamari F, Jardel C, Leclercq D, Colliot O, et al. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. *Neurobiol Aging*. 2012 Jul;33(7):1253–7.
32. Buerger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. *Brain*. 2006;129(11):3035–41.
33. Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer's disease concord with amyloid- β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. *Alzheimer's and Dementia*. 2018 Nov 1;14(11):1470–81.
34. Willemse EAJ, Tijms BM, Van Berckel BNM, Gannon S, Le Bastard N, Latham J, et al. Using cerebrospinal fluid amyloid-beta (1-42) in the memory clinic: Concordance with PET and use of biomarker ratios across immunoassays. *Alzheimer's & Dementia*. 2020 Dec;16(S5).
35. Hazan J, Wing M, Liu KY, Reeves S, Howard R. Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: A systematic review and meta-analysis. *Journal of Neurology, Neurosurgery and Psychiatry*. BMJ Publishing Group; 2022. Vol. 94, p. 113–20.
36. Bouwman FH, Frisoni GB, Johnson SC, Chen X, Engelborghs S, Ikeuchi T, et al. Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*. John Wiley and Sons Inc; 2022, Vol. 14.
37. Palmer AM. The role of the blood-CNS barrier in CNS disorders and their treatment. *Neurobiology of Disease*. 2010, Vol. 37, p. 3–12.

38. Angioni D, Delrieu J, Hansson O, Fillit H, Aisen P, Cummings J, et al. Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force. *Journal of Prevention of Alzheimer's Disease*. 2022 Oct 1;9(4):569–79.
39. Douglas Galasko, Todd E Golde. The possibility that changes in the blood reflect mechanisms of neurodegeneration in the brain, as well as the dilution of proteins and other analytes as they travel from the brain to the cerebrospinal fluid (CSF) and then into the circulation, pose a significant analytical detection challenge. *Alzheimers Res Ther* [Internet]. 2013 [cited 2023 Oct 15]; Available from: <http://alzres.com/content/5/2/10>
40. McGrowder DA, Miller F, Vaz K, Nwokocha C, Wilson-Clarke C, Anderson-Cross M, et al. Cerebrospinal fluid biomarkers of alzheimer's disease: Current evidence and future perspectives. *Brain Sciences*. MDPI AG; 2021. Vol. 11, p. 1–56.
41. Pluta R, Ułamek-Kozioł M, Januszewski S, Czuczwar SJ. Platelets, lymphocytes and erythrocytes from Alzheimer's disease patients: The quest for blood cell-based biomarkers. *Folia Neuropathologica*. Termedia Publishing House Ltd.; 2018. Vol. 56, p. 14–20.
42. Veitinger M, Varga B, Guterres SB, Zellner M. Platelets, a reliable source for peripheral Alzheimer's disease biomarkers? *Acta Neuropathol Commun*. 2014 Jan 27;2(1). doi. 10.1186/2051-5960
43. Mietelska-Porowska A, Wojda U. T Lymphocytes and Inflammatory Mediators in the Interplay between Brain and Blood in Alzheimer's Disease: Potential Pools of New Biomarkers., *Journal of Immunology Research*. Hindawi Limited; 2017.
44. Stevenson A, Lopez D, Khoo P, Kalaria RN, Mukaetova-Ladinska EB. Exploring Erythrocytes as Blood Biomarkers for Alzheimer's Disease. *Journal of Alzheimer's Disease*. IOS Press; 2017. Vol. 60, p. 845–57.